Addition of the immunotherapy drug pembrolizumab to standard of care for patients with ... The trial was funded by by a SU2C ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

PITTSBURGH — Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue ...

Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) announced “promising” preliminary results from an ongoing ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

A new report from leading contract research organisation Novotech has shed light on the current state of play in the global ...

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.